Application of GLP-1 Receptor Agonists in Cardiorenometabolic Syndrome

Nomozov, Eldorbek, Srojidinova, Nigora, Номозов, Э., Срожидинова, Н, Nomozov, Eldorbek, Srojidinova, Nigora

O‘zbekiston кardiologiyasi · 2026-yil

Annotatsiya

Cardiorenometabolic syndrome (CRMS) is one of the most important challenges in modern medicine and is considered a leading cause of morbidity and mortality worldwide. Major randomized clinical trials conducted over the past five years — SELECT (2023), FLOW (2024), and STEP-HFpEF (2023) — have provided fundamentally new insights into the cardiovascular and renal protective mechanisms of GLP-1 receptor agonists (GLP-1 RAs), particularly semaglutide. The effects of GLP-1 RAs extend beyond glycemic control and involve a multifaceted biological network targeting endothelial dysfunction, oxidative stress, NF-κB–mediated inflammation, activation of the renin–angiotensin–aldosterone system (RAAS), intraglomerular hyperfiltration, and visceral adiposity. Current clinical and mechanistic evidence provides sufficient rationale to consider this drug class as one of the key pillars of future CRMS management.

Maqola ma’lumotlari
MualliflarNomozov, Eldorbek, Srojidinova, Nigora, Номозов, Э., Срожидинова, Н, Nomozov, Eldorbek, Srojidinova, Nigora
JurnalO‘zbekiston кardiologiyasi
Nashr sanasi2026-03-30
Jild3
Son1
Betlar101-108
TilO‘zbek
DOI10.70626/cardiouz-2026-3-00082

Kalit so‘zlar

GLP-1 receptor agonists, semaglutide, cardioprotection, renoprotection, endothelial dysfunction, oxidative stress, tubuloglomerular feedback, cardiorenometabolic syndrome, SELECT, FLOW, STEP-HFpEF, агонисты рецепторов ГПП-1, семаглутид, кардиопротекция, ренопротекция, эндотелиальная дисфункция, окислительный стресс, тубулогломерулярная обратная связь, кардиоренометаболический синдром, SELECT, FLOW, STEP-HFpEF., агонисты рецепторов ГПП-1, семаглутид, кардиопротекция, ренопротекция, эндотелиальная дисфункция, окислительный стресс, тубулогломерулярная обратная связь, кардиоренометаболический синдром, SELECT, FLOW, STEP-HFpEF, GLP-1 retseptor agonistlari, semaglutid, kardioprotektsiya, renoprotektsiya, endotelial disfunksiya, oksidlovchi stress, tubuloglomerulyar qayta aloqa, kardiorenometabolik sindrom, SELECT, FLOW, STEP-HFpEF

Ilmiy soha

O‘zbekiston кardiologiyasi jurnalidan boshqa maqolalar

O‘zbekiston кardiologiyasi — barcha maqolalar